The Long Island Angel Network

Long Island Angel Network

The Long Island Angel Network is the most well known forum of angel investors on Long Island. Members can evaluate andexchange information about investment opportunities, primarily in technology- and innovation-focused early-stage and emerging growth companies in the $500,000 – $2 million range.

LI Angel Network screeners endeavors to select companies for presentation that they judge likely to be of the greatest interest to members, but the Network does not make investment recommendations; investors’ decisions are made individually. 

If you are an entrepreneur interested in presenting to the LIAN you can submit your application (via if they feel you are a fit you will be selected to pitch at their frequent “pitch nights”. You can also just attend pitch nights so what they are all about and better understand the caliber of firms you are competing with for the angels attention.


Long Island Angel Network Presentation Night

Long Island Angel NetworkIf you’re looking at presenting your venture to the Long Island Angel Network don’t miss their Presentation Night this Wednesday, March 20, 2013 from 5:30 PM to 

Attending this event will give you insight into the Long Island Angels without the pressure of presenting blind. ONLY PRESELECTED firms are presenting. Apply here to present at future events.

BioEntrepreneur‐In‐Residence (B‐EIR) Call for Applications at Stony Brook University

Stony Brook UniversityThe Center for Biotechnology (CFB) is seeking one or more highly‐motivated and experienced BioEntrepreneur(s)‐In‐Residence (B‐EIR) to launch new bioscience ventures in the Long Island region based upon commercially promising biomedical technologies emerging from Stony Brook University. The B‐EIR(s) will be responsible for the identification and evaluation of intellectual property available for license from a pre‐ screened pool of start‐up opportunities. The B‐EIR will engage directly with inventors and CFB senior staff members to determine and outline critical technical milestones to add‐value and mitigate the risk of early stage technology commercialization. The B‐EIR will ultimately select specific biomedical technologies to form the basis of one or more new companies, and will be required to develop detailed commercialization strategies, business plans and investor presentations. The B‐EIR will also (a) negotiate and execute option and/or license agreements with the Office of Technology Licensing and Industry Relations (OTLIR) as may be appropriate, (b) seek and secure capital from both public and private sources, and (c) exit from the B‐EIR program to lead the start‐up company which must be located in the Long Island region.

To help facilitate this process the CFB will:

  • Compensate the B‐EIR(s) as an independent consultant during the due diligence and technology development process,
  • Provide a modest budget for critical experiments, technology assessment and/or analysis, 
  • Facilitate access to faculty expertise and core research facilities, business incubator facilities, and business support services as needed,
  • Provide senior business development and technology commercialization staff support, as well as the support of MBA, PhD, and JD student teams to assist with market and IP assessments, competitive analyses, and financial modeling,
  • Assist with introductions to the Long Island Angel Network (LIAN), Long Island Capital Alliance (LICA), and other Angel and Venture Capital groups.

The successful B‐EIR candidate will possess domain expertise and technical proficiency in the life sciences, as well as business acumen and industry experience, particularly in early‐stage technology commercialization, new venture creation, and fundraising. Advanced degree in a life sciences field, business and/or law are preferred. Compensation and term of engagement dependent upon percentage effort, experience, and the specific start‐up opportunity selected. B‐EIRs will report to the CFB and its Advisory Board (see below). Interested parties should reply to Diane Fabel ( ), B‐EIR Search Committee, with a statement of interest and resume. Inquiries will be considered through September 30th, or until appropriate candidates are identified.

Advisory Board

  • Colin Goddard, PhD, Chairman, CEO, Coferon
  • Leah Lipsich, PhD, Executive Director, Regeneron Pharmaceuticals
  • Glenn D. Prestwich, PhD, Presidential Chair, Medicinal Chemistry, University of Utah Andrew A. Protter, PhD, VP Preclinical Development, Medivation
  • Clinton T. Rubin, PhD, Chairman, Biomedical Engineering, Stony Brook University Charles S. Ryan, JD, PhD, Senior VP & Chief Patent Counsel, Forest Laboratories